Subgroup Analysis of Phase 3 FOCUS Study Reveals Optimal Patient Selection for Melphalan/Hepatic Delivery System in Uveal Melanoma
核心洞察
Subgroup analyses from the phase 3 FOCUS study published in Journal of Cancer Research and Clinical Oncology demonstrate that patients with lower tumor burden achieve significantly higher response rates (51.1% vs. 22.2%) and longer progression-free survival (11.3 vs. 5.8 months) with melphalan/hepatic delivery system treatment.
The study found that 57.6% of patients achieving objective responses did so within the first two treatment cycles, while one-third responded in cycles 4-6, highlighting the importance of completing the full 6-cycle treatment regimen.
Overall survival was significantly longer for patients with smaller liver tumor involvement (22.4 vs 16.8 months), lower tumor burden (26.7 vs 15.4 months), and normal LDH (搜索) levels (23.4 vs 15.3 months).
Delcath Systems (搜索) has announced the publication of comprehensive subgroup analyses from the phase 3 FOCUS study, revealing critical insights for optimizing treatment selection in patients with unresectable metastatic uveal melanoma (搜索) (mUM). The analysis, published in the Journal of Cancer Research and Clinical Oncology, examined the efficacy and safety of the HEPZATO KIT (搜索) across diverse patient populations, providing clinicians with evidence-based guidance for treatment decisions.
Key Efficacy Findings Across Patient Subgroups
The prespecified analysis included 91 patients from the FOCUS study and evaluated multiple clinically relevant subgroups based on age, sex, geographic region, extent of liver involvement, hepatic tumor burden, presence of extrahepatic lesions, baseline LDH (搜索) levels, and number of prior therapies.
The most significant finding emerged in patients with tumor burden below the median, who demonstrated substantially superior outcomes across multiple endpoints. These patients achieved an overall response rate (ORR) of 51.1% compared to 22.2% in those with higher tumor burden (p=0.008). Similarly, progression-free survival was significantly longer at 11.3 months versus 5.8 months (p=0.007).
Overall survival analysis revealed three key predictive factors for improved outcomes. Patients with smaller extent of tumor liver involvement achieved a median overall survival of 22.4 months compared to 16.8 months in those with greater liver involvement (p=0.032). Those with tumor burden below the median survived 26.7 months versus 15.4 months (p=0.008), while patients with low or normal LDH (搜索) levels had a median survival of 23.4 months compared to 15.3 months in those with elevated LDH (p=0.019).
Treatment Response Patterns and Timing
The analysis provided important insights into the timing of treatment responses, with implications for treatment duration decisions. Of the 33 patients who achieved an objective response, 57.6% (19 patients) responded within the first or second treatment cycle. However, one-third of responses (33.3%; 11 patients) were observed in cycles 4-6, underscoring the importance of completing the full 6-cycle treatment regimen to optimize tumor response.
"These subgroup analyses provide valuable insights into optimizing treatment with Melphalan/HDS for patients with unresectable metastatic uveal melanoma (搜索), underscoring the importance of early intervention in patients with lower tumor burden to maximize clinical benefits," said Vojislav Vukovic, MD, MSc, PhD, Chief Medical Officer of Delcath.
Safety Profile Remains Consistent
The safety analysis demonstrated that the treatment's tolerability was maintained across all patient subgroups. The overall safety profile showed no evidence of cumulative toxicity with successive treatment cycles, and the incidence of serious adverse events and Grade 3/4 adverse events remained consistent with the overall study population. Notably, no treatment-related deaths occurred during the study.
Clinical Implications for Treatment Selection
The findings suggest that patients with lower hepatic tumor burden represent an optimal population for melphalan/hepatic delivery system treatment. The consistent efficacy observed regardless of age, sex, geographic region, presence or absence of extrahepatic lesions, and prior therapy history indicates broad applicability of the treatment across diverse patient populations.
The HEPZATO KIT (搜索) represents the only liver-directed treatment currently approved by the FDA for patients with unresectable mUM. The system combines melphalan chemotherapy with Delcath's proprietary hepatic delivery system, which isolates hepatic venous blood from systemic circulation while simultaneously filtering hepatic venous blood during drug infusion and washout.
Study Background and Regulatory Status
The FOCUS study utilized the HEPZATO KIT (搜索) and led to FDA approval of this liver-directed therapy. The treatment is approved for adult patients with metastatic uveal melanoma (搜索) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
The subgroup analyses reinforce the clinical value of this targeted approach in managing a challenging malignancy with historically limited treatment options. As Vukovic noted, "The consistent efficacy and manageable safety profile across diverse patient groups further validate this liver-directed therapy as a key option in managing this challenging disease."